Tin tức & Cập nhật
Xem bài viết Da liễu
Xem
Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis
The use of dupilumab significantly delays disease relapse in patients with moderate-to-severe atopic dermatitis (AD) while having an acceptable safety profile, reports a study.
Long-term dupilumab blocks relapse in moderate-to-severe atopic dermatitis
25 May 2026
Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients
Treatment with seladelpar for up to 2 years improves cholestatic biomarkers and pruritus in patients with primary biliary cholangitis (PBC), with no serious safety concerns noted with long-term use, as shown by interim results of the ASSURE study.
Seladelpar delivers improvements in cholestatic biomarkers, pruritus in PBC patients
09 May 2026
Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases
Treatment with ipilimumab plus nivolumab improves long-term survival in melanoma patients with asymptomatic brain metastases, according to the results of the NIBIT-M2 trial presented at AACR 2026.
Ipilimumab plus nivolumab prolongs survival in melanoma with brain metastases
05 May 2026
Deuruxolitinib improves scalp hair regrowth in patients with severe AA
Treatment with deuruxolitinib, an oral Janus kinase 1/2 inhibitor, resulted in significant hair regrowth on the scalp for 24 weeks among patients with severe alopecia areata (AA), according to the two phase III THRIVE-AA1 and -AA2 trials presented at AAD 2026.
